No Data
CONBA Pharmaceutical's Unit Gets Registration Certificate for Adenosylcobalamin Capsules
Zhejiang CONBA Pharmaceutical Gets US FDA Approval for Mucolytic Agent
Zhejiang Conba Pharmaceutical (600572.SH): Subsidiary acetylcysteine solution approved by the USA FDA.
On March 20, Gu Longhui reported that Zhejiang Conba Pharmaceutical (600572.SH) announced that its wholly-owned subsidiary Zhejiang Jinhua Conba Pharmaceutical Co., Ltd. (referred to as "Jinhua Conba") has established a wholly-owned subsidiary in the USA, Conba USA Inc. (referred to as "USA Conba"), which has received notification from the U.S. Food and Drug Administration (referred to as "FDA"). The abbreviated new drug application (ANDA, i.e., U.S. generic drug application) submitted by USA Conba for acetylcysteine solution has been approved. Acetylcysteine, as a mucolytic agent, is used to treat respiratory diseases with excessive thick mucus secretion, such as acute...
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Zhejiang CONBA Pharmaceutical Gets Registration Approval for Asthma Relief Drug
Zhejiang CONBA Pharmaceutical Co.,Ltd.'s (SHSE:600572) Shares Lagging The Market But So Is The Business
